PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial.

Abstract The LUMIRA trial evaluated the effectiveness of radiofrequency (RFA) and microwave ablation (MWA) in lung tumours ablation and defining more precisely their fields of application. It is a controlled prospective multi-centre random trial with 1:1 randomization. Fifty-two patients in stage IV disease (15 females and 37 males, mean age 69 y.o., range 40-87) were included. We randomized the patients in two different subgroups: MWA group and RFA group. For each group, we evaluated the technical and clinical success, the overall survival and complication rate. Inter-group difference was compared using Chi-square test or Fisher's exact test for categorical variables and one-way ANOVA test for continuous variables. For RFA group, there was a significant reduction in tumour size only between 6 and 12 months (p value = 0.0014). For MWA group, there was a significant reduction in tumour size between 6 and 12 months (p value = 0.0003) and between pre-therapy and 12 months (p value = 0.0215). There were not significant differences between the two groups in terms of survival time (p value = 0.883), while the pain level in MWA group was significantly less than in RFA group (1.79 < 3.25, p value = 0.0043). In conclusion, our trial confirms RFA and MWA are both excellent choices in terms of efficacy and safety in lung tumour treatments. However, when compared to RFA therapy, MWA produced a less intraprocedural pain and a significant reduction in tumour mass.
PMID
Related Publications

Complications of microwave and radiofrequency lung ablation: personal experience and review of the literature.

Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques.

Ultrasound-guided ablative therapy for hepatic malignancies : a comparison of the therapeutic effects of microwave and radiofrequency ablation.

MWA Versus RFA for Perivascular and Peribiliary CRLM: A Retrospective Patient- and Lesion-Based Analysis of Two Historical Cohorts.

Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation.

Authors

Mayor MeshTerms
Keywords

Ablation treatment

Lung cancer

Microwave

Radiofrequency

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28417355
OWN - NLM
STAT- MEDLINE
DA  - 20170418
DCOM- 20170419
LR  - 20170419
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - Radiofrequency versus microwave ablation for treatment of the lung tumours:
      LUMIRA (lung microwave radiofrequency) randomized trial.
PG  - 96
LID - 10.1007/s12032-017-0946-x [doi]
AB  - The LUMIRA trial evaluated the effectiveness of radiofrequency (RFA) and
      microwave ablation (MWA) in lung tumours ablation and defining more precisely
      their fields of application. It is a controlled prospective multi-centre random
      trial with 1:1 randomization. Fifty-two patients in stage IV disease (15 females 
      and 37 males, mean age 69 y.o., range 40-87) were included. We randomized the
      patients in two different subgroups: MWA group and RFA group. For each group, we 
      evaluated the technical and clinical success, the overall survival and
      complication rate. Inter-group difference was compared using Chi-square test or
      Fisher's exact test for categorical variables and one-way ANOVA test for
      continuous variables. For RFA group, there was a significant reduction in tumour 
      size only between 6 and 12 months (p value = 0.0014). For MWA group, there was a 
      significant reduction in tumour size between 6 and 12 months (p value = 0.0003)
      and between pre-therapy and 12 months (p value = 0.0215). There were not
      significant differences between the two groups in terms of survival time (p value
      = 0.883), while the pain level in MWA group was significantly less than in RFA
      group (1.79 &lt; 3.25, p value = 0.0043). In conclusion, our trial confirms RFA and 
      MWA are both excellent choices in terms of efficacy and safety in lung tumour
      treatments. However, when compared to RFA therapy, MWA produced a less
      intraprocedural pain and a significant reduction in tumour mass.
FAU - Macchi, M
AU  - Macchi M
AD  - Department of Radiology, Circolo e Fondazione Macchi Hospital, Insubria
      University, Varese, Italy.
FAU - Belfiore, M P
AU  - Belfiore MP
AD  - Department of Experimental Medicine, University of Campania "Luigi Vanvitelli",
      Naples, Italy.
FAU - Floridi, C
AU  - Floridi C
AD  - Radiology Department, Fatebenefratelli Hospital, Milan, Italy.
      [email protected]
FAU - Serra, N
AU  - Serra N
AD  - Department of Radiology and Radiotherapy, University of Campania "Luigi
      Vanvitelli", Naples, Italy.
FAU - Belfiore, G
AU  - Belfiore G
AD  - Department of Radiology, Sant'Anna e San Sebastiano Hospital, Caserta, Italy.
FAU - Carmignani, L
AU  - Carmignani L
AD  - Interventional Radiology Unit, San Jacopo Hospital, Pistoia, Italy.
FAU - Grasso, R F
AU  - Grasso RF
AD  - Department of Diagnostic and Interventional Radiology, Campus Bio-Medico
      University, Rome, Italy.
FAU - Mazza, E
AU  - Mazza E
AD  - Interventional Radiology Unit, Careggi Hospital, Florence, Italy.
FAU - Pusceddu, C
AU  - Pusceddu C
AD  - Division of Interventional Radiology, Department of Oncological Radiology,
      Oncological Hospital "A. Businco", Cagliari, Italy.
FAU - Brunese, L
AU  - Brunese L
AD  - Department of Radiology, University of Molise, Campobasso, Italy.
FAU - Carrafiello, G
AU  - Carrafiello G
AD  - Department of Radiology, San Paolo Hospital, University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170418
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Catheter Ablation/*methods
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/pathology/*surgery
MH  - Male
MH  - Microwaves/*therapeutic use
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prospective Studies
OTO - NOTNLM
OT  - *Ablation treatment
OT  - *Lung cancer
OT  - *Microwave
OT  - *Radiofrequency
EDAT- 2017/04/19 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/02/27 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1007/s12032-017-0946-x [doi]
AID - 10.1007/s12032-017-0946-x [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):96. doi: 10.1007/s12032-017-0946-x. Epub 2017 Apr 18.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>